LumiThera announced today that it closed the second tranche of its Series C financing round with more than $10 million raised. The photobiomodulation (PBM) treatment developer earmarked the proceeds from the funding round for further clinical testing and commercialization of its Valeda light delivery system for treating dry age-related macular degeneration (AMD). LumiThera’s Valeda system […]
LumiThera inks Italian Valeda distro deal
LumiThera said today that it inked a deal with ophthalmology distributor Miloftalmica to be the exclusive distributor of the Valeda light delivery system, intended to treat dry age-related macular degeneration, across Italy. Therapy using the Valeda light delivery system consists of a series of light-based treatments to the retinal cells, which Seattle-based LumiThera claims improves […]
LumiThera inks distro deal with Nikon’s Optos
LumiThera said today it inked a distribution deal with Nikon (TYO:7731) subsidiary Optos to distribute its Valeda light delivery system intended for use in treating dry age-related macular degeneration. The deal will position Optos as the exclusive distributor of the device in 12 European countries, the Seattle-based company said. The device has already won CE Mark approval in the […]
5 medtech stories we missed this week: July 6, 2018
From Zetta getting FDA clearance to Prescient Medical receiving CE Mark approval, here are five medtech stories we missed this week but thought were still worth mentioning. 1. Zetta wins FDA clearance for Zoom MRI software Zetta announced in a June 25 press release that its MRI software has received FDA 510(k) clearance. The software, known […]
LumiThera touts interim data from pilot study of LT-300 AMD treatment
LumiThera today announced topline interim results from the Lightsite 1 trial of its LT-300 photobiomodulation device designed to treat dry age-related macular degeneration, touting statistically significant vision benefits maintained to 3 months. Data came from the 30-patient pilot study of the device, funded by a Small Business Innovation Research grant from the National Institute of Health […]
LumiThera raises $6m in Series B
LumiThera said today it raised $5.5 million in a Series B round of financing to support the development of its LT-300 device designed for treating dry age-related macular degeneration. Proceeds from the round will support pursuit of regulatory clearance for the LT-300 device outside the US, including CE Mark approval in the European Union and additional […]
LumiThera wins Health Canada nod for photobiomodulation trial
LumiThera said today it won Health Canada approval for its Lightsite clinical trial examining the effect of its non-invasive photobiomodulation treatment in patients with age-related macular degeneration. The Seattle-based company’s study is being sponsored by a grant from the National Institute of Health and the division of the National Eye Institute. “The design of the study […]
Biolase lures Zimmer Dental prez Flynn for CEO role | Personnel Moves
